Therapy Areas: Oncology
Quanterix Raises USD 69m from Public Offering
16 August 2019 - - US-based Quanterix Corp. (NASDAQ: QTRX), a company digitising biomarker analysis with the goal of advancing the science of precision health, has closed its underwritten public offering of 2,732,673 shares of its common stock at a public offering price of USD 25.25 per share, including 356,435 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, the company said.

Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately USD 69m.

J.P. Morgan Securities LLC and SVB Leerink LLC acted as joint book-running managers for the offering. Canaccord Genuity LLC acted as co-manager for the offering. Perella Weinberg Partners acted as independent capital markets advisor to Quanterix for the offering.

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health.

The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease.

Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.


Related Headlines